
Mallinckrodt Investor Relations Material
Latest events

Q2 2025
Mallinckrodt
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mallinckrodt plc
Access all reports
Mallinckrodt plc is a specialty pharmaceutical company that focuses on developing, manufacturing, and commercializing treatments for autoimmune and rare diseases, as well as therapies for pain management and critical care. The company’s portfolio includes a range of branded and generic pharmaceuticals, with a strong emphasis on specialty therapies for conditions such as neurology, nephrology, rheumatology, and pulmonology. Mallinckrodt also offers imaging agents used in diagnostic procedures. Its products are primarily distributed to hospitals, physicians, and healthcare providers. The company is headquartered in Dublin, Ireland, and its shares are listed on the New York Stock Exchange.
Key slides for Mallinckrodt plc


M&A Announcement
Mallinckrodt plc


M&A Announcement
Mallinckrodt plc
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
MNK
Country
🇺🇸 United States